Mentice AB (MNTC) AI Stock Analysis

• Market Cap: kr381.10M
• Dividend Yield: N/A
• Average Volume (3M): 19.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -0.02%
• EPS Growth: -85.98%
• Country: SE
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.46
• Shares Outstanding: 28,125,734
• 10 Day Avg. Volume: 26,429
• 30 Day Avg. Volume: 19,315
• PEG Ratio: -0.19
• Price to Book (P/B): 2.71
• Price to Sales (P/S): 1.34
• P/FCF Ratio: -14.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.09
• Revenue Forecast (FY): kr308.01M

• Rating: 56 Neutral
• Price Target: kr14.00 ▲(4.48% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

The score is held back primarily by weak financial performance—persistent losses, margin volatility, and a return to cash burn in 2025—despite a relatively serviceable balance sheet. Technicals are a meaningful offset with a bullish trend (price above key moving averages and positive MACD). Valuation remains constrained because earnings are negative and no dividend yield is provided.

Positive Factors

Specialized product niche (endovascular simulation)

A focused product suite for endovascular and minimally invasive procedure simulation creates durable competitive advantage through specialized IP, clinical validation needs and integration with clinical training workflows. This niche orientation supports sustained demand from hospitals, training centers and device partners over months to years.

Negative Factors

Persistent losses and volatile margins

Ongoing net losses and erratic margins signal structural issues in cost structure, pricing or product mix that hinder ability to convert revenue into sustainable profits. Over months this undermines return on invested capital, limits reinvestment ability and raises execution risk unless margins recover.

Mentice AB Business Overview & Revenue Model

Company Description

Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It...

Read more

Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It...

How the Company Makes Money

Mentice makes money primarily by selling and licensing simulation solutions used for interventional procedure training and planning. Key revenue streams typically include: (1) sales of simulation systems that bundle proprietary software with compa...

Read more

Mentice makes money primarily by selling and licensing simulation solutions used for interventional procedure training and planning. Key revenue streams typically include: (1) sales of simulation systems that bundle proprietary software with compa...

Mentice AB Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	279.09M	290.33M	273.61M	217.95M	185.06M
Gross Profit	-33.06M	257.25M	236.38M	188.94M	149.92M
EBITDA	-1.72M	18.30M	28.87M	266.00K	1.44M
Net Income	-32.33M	-18.42M	-2.82M	-30.66M	-29.19M
Balance Sheet
Total Assets	312.02M	323.90M	322.53M	332.98M	261.90M
Cash, Cash Equivalents and Short-Term Investments	33.38M	53.59M	59.12M	47.28M	12.70M
Total Debt	26.15M	9.14M	9.56M	16.68M	14.70M
Total Liabilities	173.65M	180.24M	163.55M	170.34M	125.02M
Stockholders Equity	138.38M	143.66M	158.97M	162.63M	136.89M
Cash Flow
Free Cash Flow	-25.43M	1.48M	29.53M	1.85M	-31.03M
Operating Cash Flow	-20.30M	17.92M	36.52M	14.91M	-5.13M
Investing Cash Flow	-15.46M	-16.44M	-16.18M	-32.28M	-25.90M
Financing Cash Flow	19.66M	-9.31M	-7.05M	48.99M	-5.78M

Mentice AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Positive. The current price of 13.4 is below the 20-day moving average (MA) of 13.53, below the 50-day MA of 13.56, and above the 200-day MA of 13.22, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 46.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MNTC.

Mentice AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MNTC	56 Neutral	kr381.10M	-11.61	-27.25%	―	-0.02%	-85.98%
CRAD.B	55 Neutral	kr881.32M	103.06	6.93%	―	-5.80%	-65.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACARIX	48 Neutral	kr303.86M	-6.28	-104.38%	―	21.88%	48.86%
BACTI.B	46 Neutral	kr586.99M	13.94	-2.52%	―	-8.10%	62.08%
BRAIN	46 Neutral	kr220.74M	-4.05	-27.22%	―	16.38%	35.71%
CLS.B	44 Neutral	kr156.46M	-4.28	-61.62%	―	14.18%	72.73%